SIETES :: 92854 citas

Resultados de la búsqueda por PSIQUIATRÍA REFINAR BÚSQUEDA

1.

Dalsgaard S, Thorsteinsson E, Trabjerg BB, Schullehner J, Plana-Ripoll O, Brikell I, Wimberley T, Thygesen M, Bang Madsen K, Timmerman A, Schendel D, McGrath JJ, Mortensen PB, Pedersen CB. Incidence rates and cumulative incidences of the full spectrum of diagnosed mental disorders in childhood and adolescence. JAMA Psychiatry 2019:20 de noviembre. [Ref.ID 103222]

2.

Ji Y, Azuine RE, Zhang Y, Hou W, Hong X, Wang G, Riley A, Pearson C, Zuckerman B, Wang X. Association of cord plasma biomarkers of in utero acetaminophen exposure with risk of attention-deficit/hyperactivity disorder and autism spectrum disorder in childhood. JAMA Psychiatry 2019:30 de octubre. [Ref.ID 103208]

3.

Iacobucci G. NICE updates antidepressant guidelines to reflect severity and length of withdrawal symptoms. BMJ 2019;367:18 de octubre. [Ref.ID 103202]

4.

Moncrieff J. Re: Esketamine for treatment resistant depression. Putting drug company interests over the public good. BMJ 2019;366:23 de septiembre. [Ref.ID 103196]

5.

Waxmonsky JG, Pelham W 3rd, Campa A, Waschbusch DA, Li T, Marshall R, Babocsai L, Humphery H, Gnagy E, Swanson J, Hanc T, Fallahazad N, Pelham WE 4th. A randomized controlled trial of interventions for growth suppression in children with attention-deficit/hyperactivity disorder treated with central nervous system stimulants. J Am Acad Child Adolesc Psychiatry 2019:29 de agosto. [Ref.ID 103191]

6.

Young K. No evidence haloperidol helps in hospital delirium. Journal Watch 2019:3 de septiembre. [Ref.ID 103168]

7.

Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, Mazzucco C, Hough D, Thase ME, Shelton RC, Molero P, Vieta E, Bajbouj M, Manji H, Drevets WC, Singh JB. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry 2019;176:1 de junio. [Ref.ID 103133]

8.

Freeman TP, Hindocha C, Green SF, Bloomfield MAP. Medicinal use of cannabis based products and cannabinoids. BMJ 2019;365:4 de abril. [Ref.ID 103086]

9.

Cortese S. Psychosis during attention deficit–hyperactivity disorder treatment with stimulants. N Engl J Med 2019;380:21 de marzo. [Ref.ID 103068]

10.

Moran LV, Ongur D, Hsu J, Castro VM, Perlis RH, Schneeweiss S. Psychosis with methylphenidate or amphetamine in patients with ADHD. N Engl J Med 2019;380:21 de marzo. [Ref.ID 103067]

11.

Josephson CB, Engbers JDT, Jette N, Patten SB, Sinqh S, Sajobi TT, Marshall D, Agha-Khani Y, Federico P, Mackie A, Macrodimitris S, McLane B, Pillay N, Sharma R, Wiebe S. Prediction tools for psychiatric adverse effects after levetiracetam prescription. JAMA Neurology 2019:enero. [Ref.ID 103020]

12.

Attia E, Steinglass JE, Walsh BT, Wang Y, Wu P, Schreyer C, Wildes J, Yilmaz Z, Guarda AS, Kaplan AS, Marcus MD. Olanzapine versus placebo in adult outpatients with anorexia nervosa: a randomized clinical trial. Am J Psychiatry 2019:18 de enero. [Ref.ID 103015]

13.

Ray WA, Stein CM, Murray KT, Fuchs DC, Patrick SW, Daugherty J, Hall K, Cooper WO. Association of antipsychotic treatment with risk of unexpected death among children and youths. JAMA Psychiatry 2018:12 de diciembre. [Ref.ID 102895]

14.

Cortese A, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, Atkinson LZ, Tessari L, Banaschewski T, Coghill D, Hollis C, Simonoff E, Zuddas A, Barbui C, Purgato M, Steinhausen HC, Shokraneh F, Xia J, Cipriani A. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 2018:7 de agosto. [Ref.ID 102788]

15.

Viktorin A, Levine SZ, Altemus M, Reichenberg A, Sandin S. Paternal use of antidepressants and offspring outcomes in Sweden: nationwide prospective cohort study. BMJ 2018;361:k2233. [Ref.ID 102749]

16.

Anónimo. Valproato (Depakine / Depakine Crono): programa de prevención de embarazos. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2018:24 de julio. [Ref.ID 102721]

17.

Kerr MP. Guidance is needed on valproate in pregnancy for those without capacity. BMJ 2018;361:29 de mayo. [Ref.ID 102684]

18.

Braillon A, Bewley S. Prescribing in pregnancy shows the weaknesses in pharmacovigilance. BMJ 2018;361:29 de mayo. [Ref.ID 102683]

19.

Angus-Leppan H, Liu RSN. Weighing the risks of valproate in women who could become pregnant. BMJ 2018;361:18 de abril. [Ref.ID 102682]

20.

Mammen G, Rueda S, Roerecke M, Bonato S, Lev-Ran S, Rehm J. Association of Cannabis with long-term clinical symptoms in anxiety and mood disorders: a systematic review of prospective studies. J Clin Psychiatry 2018;79:5 de junio. [Ref.ID 102666]